본문 바로가기
KERD
논문KCI 등재

Proton Pump Inhibitor-Related Gastric Mucosal Changes

김광하
거트앤리버 소화기연관학회협의회|2021.09|Gut and Liver|제15권 제5호|pp. 646-652|DOI 10.5009/gnl20036

2

조회

0

다운로드

11

인용

0

참고문헌

키워드

EndoscopyStomachProton pump inhibitorLong-term adverse effects

초록

Proton pump inhibitors (PPIs) are used worldwide to treat of acid-related disorders such as peptic ulcer and gastroesophageal reflux disease and to prevent gastroduodenal injuries due to nonsteroidal anti-inflammatory drugs. PPIs are the most potent inhibitors of gastric acid secretion currently available, and they are one of the most commonly prescribed classes of drugs because of their high efficacy and low toxicity. However, long-term PPI use causes histopathological changes such as parietal cell protrusion into the gland lumen, cystic dilation of gastric fundic glands, and foveolar epithelial hyperplasia. These changes can manifest on endoscopic examination as fundic gland polyps, hyperplastic polyps, multiple white and flat elevated lesions, cobblestone-like mucosa, or black spots. Clinicians must be aware of PPI-induced endoscopic features in patients with chronic long-term PPI use. Conversely, identifying patients with long-term PPI use based on their endoscopic findings is important. Recently, potassium-competitive acid blockers (P-CABs), a new class of acid suppressants that inhibit gastric acid secretion more strongly than PPIs, have recently been introduced clinically. Further long-term prospective studies on these gastric mucosal lesions in patients with either PPI or P-CAB use are required to investigate their association with histopathological changes and to establish the clinical significance of these findings.

Abstract

Proton pump inhibitors (PPIs) are used worldwide to treat of acid-related disorders such as peptic ulcer and gastroesophageal reflux disease and to prevent gastroduodenal injuries due to nonsteroidal anti-inflammatory drugs. PPIs are the most potent inhibitors of gastric acid secretion currently available, and they are one of the most commonly prescribed classes of drugs because of their high efficacy and low toxicity. However, long-term PPI use causes histopathological changes such as parietal cell protrusion into the gland lumen, cystic dilation of gastric fundic glands, and foveolar epithelial hyperplasia. These changes can manifest on endoscopic examination as fundic gland polyps, hyperplastic polyps, multiple white and flat elevated lesions, cobblestone-like mucosa, or black spots. Clinicians must be aware of PPI-induced endoscopic features in patients with chronic long-term PPI use. Conversely, identifying patients with long-term PPI use based on their endoscopic findings is important. Recently, potassium-competitive acid blockers (P-CABs), a new class of acid suppressants that inhibit gastric acid secretion more strongly than PPIs, have recently been introduced clinically. Further long-term prospective studies on these gastric mucosal lesions in patients with either PPI or P-CAB use are required to investigate their association with histopathological changes and to establish the clinical significance of these findings.

참고문헌 (40)

  1. Heidelbaugh JJ, "Overutilization of proton-pump inhibitors : what the clinician needs to know", Therap Adv Gastroenterol, 5, pp.219~232 (2012)
  2. Nocon M, "Long-term treatment of patients with gastro-oesophageal reflux disease in routine care : results from the ProGERD study", Aliment Pharmacol Ther, 25, pp.715~722 (2007)
  3. Pounder R, "Drug-induced changes of plasma gastrin concentration", Gastroenterol Clin North Am, 19, pp.141~153 (1990)
  4. Wang TC, "Processing and proliferative effects of human progastrin in transgenic mice", J Clin Invest, 98, pp.1918~1929 (1996)
  5. Graham DY, "Long-term proton pump inhibitor use and gastrointestinal cancer", Curr Gastroenterol Rep, 10, pp.543~547 (2008)
  6. Kamada T, "Helicobacter pylori infection and endoscopic gastritis : Kyoto classification of gastritis", Nihon Shokakibyo Gakkai Zasshi, 112, pp.982~993 (2015)
  7. Stolte M, "Omeprazole-induced pseudohypertrophy of gastric parietal cells", Z Gastroenterol, 30, pp.134~138 (1992)
  8. Declich P, "Parietal cell hyperplasia with deep cystic dilations : a lesion closely mimicking fundic gland polyps", Am J Gastroenterol, 95, pp.566~568 (2000)
  9. Jalving M, "Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy", Aliment Pharmacol Ther, 24, pp.1341~1348 (2006)
  10. Kiso M, "Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor : a multicenter study", Scand J Gastroenterol, 52, pp.828~832 (2017)
  11. Miyamoto S, "Gastric hyperplastic polyps associated with proton pump inhibitor use in a case without a history of Helicobacter pylori infection", Intern Med, 56, pp.1825~1829 (2017)
  12. Hatano Y, "Factors associated with gastric black spot, white flat elevated mucosa, and cobblestone-like mucosa : a cross-sectional study", Digestion, 98, pp.185~193 (2018)
  13. Cats A, "Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment", Hum Pathol, 31, pp.684~690 (2000)
  14. Krishnamurthy S, "Parietal cell protrusions in gastric ulcer disease", Hum Pathol, 28, pp.1126~1130 (1997)
  15. Ang ST, "Long-term omeprazole therapy in patients with Barrett’s esophagus is associated with parietal cell hyperplasia", Gastroenterology, 106, pp.A1016~ (1994)
  16. Shiotani A, "Hypergastrinemia in long-term use of proton pump inhibitors", Digestion, 97, pp.154~162 (2018)
  17. Synnerstad I, "Omeprazole induces high intraglandular pressure in the rat gastric mucosa", Gastroenterology, 112, pp.1221~1230 (1997)
  18. Tran-Duy A, "Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer : systematic review and metaanalysis", Clin Gastroenterol Hepatol, 14, pp.1706~1719 (2016)
  19. Stolte M, "Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment", Z Gastroenterol, 33, pp.146~149 (1995)
  20. el-Zimaity HM, "Fundic gland polyps developing during omeprazole therapy", Am J Gastroenterol, 92, pp.1858~1860 (1997)
  21. Dockray GJ, "Topical review: gastrin and gastric epithelial physiology", J Physiol, 518(Pt 2), pp.315~324 (1999)
  22. Fukuda M, "Histological analy-sis of fundic gland polyps secondary to PPI therapy", Histopathology, 75, pp.537~545 (2019)
  23. Choudhry U, "Proton pump inhibitor-associated gastric polyps : a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics", Am J Clin Pathol, 110, pp.615~621 (1998)
  24. Hongo M, "Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan", J Gastroenterol, 45, pp.618~624 (2010)
  25. Haruma K, "Kyoto classification of gastritis" (2019), Nihon Medical Center
  26. Graham JR, "Gastric polyposis : onset during long-term therapy with omeprazole", Med J Aust, 157, pp.287~288 (1992)
  27. Mogadam M, "Long-term use of omeprazole is associated with development of benign epithelial gastric polyps", Am J Gastroenterol, 91, pp.A151~ (1996)
  28. Martin FC, "Systematic review with meta-analysis : fundic gland polyps and proton pump inhibitors", Aliment Pharmacol Ther, 44, pp.915~925 (2016)
  29. Kato K, "Successful treatment of proton pump inhibitor induced sporadic fundic gland polyps with an argon plasma coagulator in a patient with polycythaemia vera", Int J Surg Case Rep, 33, pp.75~78 (2017)
  30. 박영주, "Proton pump inhibitor-induced fundic gland polyposis", The Korean Journal of Internal Medicine, 32(1), pp.197~198 (2017), 대한내과학회[DOI]
  31. Nakagawa M, "Endoscopic features of gastric adenocarcinoma of fundic gland type", Stomach Intestine, 50, pp.1521~1531 (2015)
  32. Takamura A, "High expression of gastrin receptor protein in injured mucosa of Helicobacter pyloripositive gastritis", Dig Dis Sci, 58, pp.634~640 (2013)
  33. Majima K, "Multiple white and flat elevated lesions observed in the stomach : a prospective study of clinical characteristics and risk factors", Intern Med, 57, pp.2613~2619 (2018)
  34. Rino Hasegawa, "Magnified Endoscopic Findings of Multiple White Flat Lesions: A New Subtype of Gastric Hyperplastic Polyps in the Stomach", Clinical Endoscopy, 51(6), pp.558~562 (2018), 대한소화기내시경학회
  35. Adachi K, "Prevalence of multiple white and flat elevated lesions in individuals undergoing a medical checkup", Intern Med, 57, pp.1213~1218 (2018)
  36. Uedo N, "Multiple white flat lesions in the gastric corpus are not intestinal metaplasia", Endoscopy, 49, pp.615~616 (2017)
  37. Miyamoto S, "Gastric mucosal cracked and cobblestone-like changes resulting from proton pump inhibitor use", Dig Endosc, 29, pp.307~313 (2017)
  38. Takahari K, "Proton pump inhibitor induction of gastric cobblestone-like lesions in the stomach", Intern Med, 56, pp.2699~2703 (2017)
  39. Miyamoto S, "Endoscopic ultrasonography features of gastric mucosal cobblestone-like changes from a proton-pump inhibitor", Clin J Gastroenterol, 10, pp.220~223 (2017)
  40. Hatano Y, "Black spot, a novel gastric finding potentially induced by proton pump inhibitors", Intern Med, 55, pp.3079~3084 (2016)

이 간행물의 다른 논문 (17건)

Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease김은수pp. 637-638Is the Long-term Disease Course of Elderly-Onset Ulcerative Colitis Different from That of Non-Elderly-Onset Ulcerative Colitis?김은수, Lee Jin Wookpp. 639-640Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?천재희, Park Jihyepp. 641-642Whether Slow-Pull-Back or Standard Suction, Optimal Histologic Core Procurement Is Most Important Factor Rather than Blood Contamination or Cellularity in Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreatic Solid Tumor박세우pp. 643-645Overview of Helicobacter pylori Infection in Indonesia: What Distinguishes It from Countries with High Gastric Cancer Incidence?Waskito Langgeng Agung, Fauzia Kartika Afrida, Mahmudah Isna, Doohan Dalla, Khomsan Ali, Ratnasari Neneng, Rezkitha Yudith Annisa Ayu, Adnyana I Ketut, Miftahussurur Muhammadpp. 653-665
원문 보기